To determine if this represents an adaptive response suggesting vulnerability to phagocytosis, we examined untreated and HOSU-53–treated AML cells together with the B6H12 antibody that interferes with binding of SIRP-α on murine macrophages with tumor CD47. This evidence concerns the gene SIRPA and acute myeloid leukemia.